| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 江苏康缘药业股份有限公司是集中药研发、生产、销售为一体的大型中药企业，国家重点高新技术企业、国家技术创新示范企业，中国制药工业百强企业（第29位），全国中药企业十强第五位，中国医药企业创新力二十强，现有员工5000余人。建有“中药制药过程新技术国家重点实验室”等多个国家级科研平台，2018年，实验室获评“优秀类企业国家重点实验室”（医药领域第一）。先后获得国家级中药新药47个，发明专利授权331件；承担科技项目50余项；获国家技术发明二等奖1项、国家科技进步二等奖2项、省部级科技进步一等奖8项（其中江苏省科技进步一等奖2项）；研发实力连续三年位列“中药研发实力排行榜”首位。桂枝茯苓胶囊已完成美国Ⅱ期临床试验，是我国中药国际化示范品种。 公司秉承“振兴国药、报效祖国”的历史使命，在几十年的发展历程中形成了以“中药、化学药、生物制药”集群创新发展为主线，以中医药文化养生产业和健康产品为两翼的发展体系。实现大健康产业“素质提升”和“规模扩张”同步发展，全面提升企业核心竞争力。 | ||||||||||||||||||||||||
| Main Business | 药品的研发、生产与销售 | ||||||||||||||||||||||||
| Legal Representative | 肖伟 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 高海鑫 | ||||||||||||||||||||||||
| Solicitors | 江苏世纪同仁律师事务所 | ||||||||||||||||||||||||
| Auditors | 立信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0518-85521990 | ||||||||||||||||||||||||
| Fax No | 0518-85521990 | ||||||||||||||||||||||||
| Website | www.kanion.com | ||||||||||||||||||||||||
| fzb@kanion.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 18/09/2002 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.930 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.372 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 8.880 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 11.119B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |